Analyst Downgrades Affymetrix Despite 13-Percent Q1 Revenue Increase | GenomeWeb

NEW YORK, April 22 (GenomeWeb News) - An analyst at Robert W. Baird downgraded Affymetrix's stock this morning to "neutral" from "outperform," causing shares in the microarray company to fall 6 percent in early-morning trading.

 

The stock recovered some of the slide, trading down 2.46, or $1.13, at $44.88 in heavy volume in the mid-afternoon.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.